Home › NDC Lookup › Ingredients › Mucor Plumbeus › 49643-0166-30
Mucor plumbeus .1 g/mL Liquid, 30 mL Vial — NDC 49643-0166-30 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 49643-0166-30: Mucor plumbeus .1 g/mL Liquid, 30 mL Vial

by Allermed Laboratories, Inc.

This is a package of 30 mL of Mucor plumbeus .1 g/mL Liquid from Allermed Laboratories, Inc., first listed with the FDA Mar 1974 and currently FDA-listed.

🏷️ FDA NDC (as labeled) 49643-166-30 billing pads the product segment with a zero
This package
Contains30 mL Pack sizes4 compare ↓
Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Oct 22, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 49643-166-30 alone.

Record
FDA NDC Directory package listing · Non-standardized allergenic
Code segments
49643 labeler · 166 product · 30 package
Package marketed since
Mar 12, 1974
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 4964316630 9
FDA record last changed
Oct 22, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 49643-166-30
Product NDC 49643-166
11-digit billing NDC 49643016630
Application # BLA102211
SPL Set ID 3fcd2d66-dea7-0ea4-e054-00144ff8d46c
Established class (EPC) Non-Standardized Fungal Allergenic Extract
Physiologic effect Cell-mediated Immunity; Increased Histamine Release; Increased IgG Production
Chemical class Allergens; Fungal Proteins
DEA schedule Non-controlled
Marketing category BLA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 1974-03-12
Route PERCUTANEOUS, SUBCUTANEOUS
Dosage form LIQUID
Substance MUCOR PLUMBEUS
Why two NDCs? The FDA registers this code as 49643-166-30 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 49643-0166-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 5 ml 10 ml 50 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
49643-0166-05 49643-166-05 Main listing 5 mL in 1 VIAL, MULTI-DOSE 1974-03-12 — Active
49643-0166-10 49643-166-10 10 mL in 1 VIAL, MULTI-DOSE 1974-03-12 — Active
49643-0166-30 You're viewing this 30 mL in 1 VIAL, MULTI-DOSE 1974-03-12 — Active
49643-0166-50 49643-166-50 50 mL in 1 VIAL, MULTI-DOSE 1974-03-12 — Active

You're viewing one of 4 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This package contains 30 mL — 30 ml in 1 vial, multi-dose.
How does this package differ from NDC 49643-0166-05?
Both are Mucor plumbeus .1 g/mL Liquid — the drug itself is identical. This page's package is the 30 mL one, while NDC 49643-0166-05 is the 5 ml package.
What NDC number is used to bill for this package of Mucor plumbeus .1 g/mL Liquid?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Mucor plumbeus .1 g/mLthis 49643-0166-30 Allermed 30 ml — — FDA listed —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
1974
Listed with the FDA since
Mar 1974
📍
2026
Currently FDA-listed
52 years listed
🧬
·
Biosimilars
see Purple Book
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • 0.5 g / 1 mL UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • 0.004 g / 1 mL UNII 339NCG44TV
    Phenol is a chemical compound derived from coal tar or petroleum. It serves as a preservative and antimicrobial agent in medicines, helping prevent bacterial and fungal growth to keep the product stable and safe during storage.
  • 0.00125 g / 1 mL UNII 8MDF5V39QO
    A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
  • 0.0025 g / 1 mL UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAllermed Laboratories, Inc.
FDA applicationBLA102211 (BLA)
Labeler code49643
First marketedMar 1974
Product typeNon-standardized Allergenic
Portfolio199 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning 217 words ▾

WARNINGS WARNINGS This allergenic product is intended for use by physicians who are experienced in the administration of allergenic extracts and the emergency care of anaphylaxis, or for use under the guidance of an allergy specialist. This allergenic extract is not directly interchangeable with other allergenic extracts. The initial dose must be based on skin testing as described in the dosage and administration section of this insert.

Patients being switched from other types of extracts, such as alum precipitated extracts, should be started as though they were coming under treatment for the first time. Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician's office if reaction symptoms occur. As with all allergenic extracts, severe systemic reactions may occur.

In certain individuals these reactions may be life threatening. Patients should be observed for at least 20 minutes following treatment, and emergency measures as well as personnel trained in their use should be immediately available in the event of a life threatening reaction. This product should not be injected intravenously (see Dosage and Administration ).

Refer also to the Warnings , Precautions , Adverse Reactions and Overdosage sections below. Serious adverse reactions to this product should be reported to MEDWATCH, Food and Drug Administration, 5600 Fishers Lane, MD 20852-9787. Telephone 1-800-822-7967 or www.vaers.hhs.gov.

🎯 Indications and Usage 115 words ▾

INDICATIONS AND USAGE Allergenic extract may be used as a diagnostic skin test reagent in persons suspected of being sensitive to the allergenic source material from which the extract is made. Skin tests should be used in conjunction with a thorough allergic history to establish the relevance of a given allergen in the etiology of allergic disease.(4,5,6) Immunotherapy with allergenic extract is indicated in persons suffering from allergic rhinitis, bronchitis, conjunctivitis, urticaria and asthma. The therapeutic efficacy of allergenic extract has been proven in ragweed, grass, and mountain cedar pollinosis, cat-induced asthma and hypersensitivity to hymenoptera venoms.(7-12) Immunotherapy may be used along with or exclusive of antihistamines and other medications used to control allergic symptoms.

⏱️ Dosage and Administration ~3 min read ▾

DOSAGE AND ADMINISTRATION Diagnosis: Concentrated extract may be used for scratch or prick testing. Provided that the patient is not extremely sensitive, concentrated extract may be used for scratch or prick testing. In the case of extreme sensitivity, the extract should be diluted 10 fold before a scratch or prick test is performed.

Extract for intradermal testing must be used as follows: a. Patients with positive scratch or prick tests : It is not advisable to perform an intradermal skin test if the patient has a positive scratch or prick test. b. Patients with a negative scratch or prick test: Patients who do not react who do not react to a valid scratch or prick test should be tested intradermally with 0.05 mL of a 1:1000 v/v dilution of the concentrate.

If the test is negative, a second test should be performed with 0.05 mL of a 1:100 v/v dilution or concentrate. c. Patients tested only by the intradermal method : Patients suspected of being highly allergic should be tested with 0.05 mL of a 1:100,000 v/v dilution of the concentrate. A negative test should be followed by repeat tests using 10 fold stronger concentrations until the maximum dose of 0.05 mL of a 1:100 v/v dilution is reached.

Interpretation of Results Scratch and Prick Test A negative test shows only a slight red area at the site of scarification or prick penetration. Positive tests are scored as follows: 1+ Erythema with 5 mm wheal 2+ Erythema with a 5-10 mm wheal 3+ Erythema with a 10-15 mm wheal 4+ Erythema with a wheal 15 mm (or larger) with pseudopodia Intradermal Test A negative test shows no change in the appearance and size of the 5 mm wheal created by the I.D. injection of 0.05 mL of extract. Positive tests are scored as follows: 1+ Erythema 10-20 mm with a 5-10 mm wheal 2+ Erythema 20-30 mm with a 5-10 mm wheal 3+ Erythema 30-40 mm with a 10-15 mm wheal 4+ Erythema greater than 40 mm with a 15 mm wheal (or larger) with pseudopodia Immunotherapy Allergenic extract should be administered subcutaneously in the outer aspect of the upper arm using a sterile tuberculin syringe and needle.

The skin should be cleaned with 70% alcohol and aseptic technique should be observed in removing the extract from the vial. Care must be taken to avoid injecting the extract into a blood vessel because of the risk of anaphylaxis. Concentrated extract must be diluted before administration to new patients.

A 1:100,000 v/v dilution of concentrate is usually satisfactory to start treatment. However, as a precaution against overdose, a skin test with the intended starting dose should be done to help evaluate the patient's sensitivity to the product. If the skin response is larger than 5 mm edema/15 mm erythema, the extract is too strong and must be diluted before it is given subcutaneously.

The doses shown in the Suggested Dosage Schedule below are recommended unless the patient's skin test response and allergic history indicates that more dilute extract should be used. Little is known about the required accumulated dosage of allergen that is needed to relieve symptoms. However, studies have shown that high dose immunotherapy is efficacious in the treatment of allergic rhinitis and asthma.

For this reason, treatment with extract from Vial #5 is recommended, providing the patient can tolerate the extract without experiencing local or systemic reactions. Treatment with Vial #6 may be used for patients who have not had adverse reactions to extract in Vial #5 and who require more concentrated extract to control or relieve symptoms. Patients who have received allergenic extract for maintenance therapy SHOULD NOT be given the same dose from a fresh vial of extract.

IT IS ADVISABLE TO REDUCE THE DOSAGE OF FRESH EXTRACT TO ONE-FOURTH THE AMOUNT GIVEN FROM A PREVIOUS LOT OF EXTRACT MADE AT THE SAME CONCENTRATION AND BY THE SAME FORMULA. Suggested Dosage Schedule No. Vial #1 1:100,000 v/v frequency twice weekly mL Vial #2 1:10,000 v/v frequency twice weekly mL Vial #3 1:1,000 v/v freq… [Excerpted — this section continues on DailyMed.]

⛔ Contraindications ~1 min read ▾

CONTRAINDICATIONS Allergenic extract should not be administered to a non-allergic person. However, there are no absolute contraindications to the use of allergenic extract for treatment in appropriate individuals. Relative contraindications include: EXTREME SENSITIVITY TO AN ALLERGEN - Determined from the allergic history, or from previous anaphylaxis following skin testing or subcutaneous injection; AUTOIMMUNE DISEASE - Individuals with autoimmune disease may be at risk, due to the possibility of routine immunizations exacerbating symptoms of the underlying disease; PREGNANCY - In limited controlled studies of women receiving allergenic extract during conception and throughout all trimesters of pregnancy, no evidence was found that extract is harmful to the fetus or mother.

However, because of the known pharmacologic action of histamine on uterine muscle, any treatment that might result in the release of significant amounts of this mediator should be avoided if possible (13). See Precaution #4; MYOCARDIAL INFARCTION - Patients who have experienced a recent myocardial infarction may not be able to tolerate immunotherapy. As in all of the above circumstances, the benefit to risk ratio must be carefully evaluated; BLEEDING DIATHESIS - Patients with a bleeding tendency should not be tested or treated with allergenic extract, unless the physician responsible believes that such procedures are safe to perform.

Allergenic extract should be temporarily withheld from patients if any of the following conditions exist: (1) severe symptoms of hay fever and/or asthma; (2) infection or flu accompanied by fever; and (3) exposure to excessive amounts of clinically relevant allergens prior to skin testing or immunotherapy.

⚠️ Warnings 207 words ▾

WARNINGS The only approved method for determining hypersensitivity to Allermed Laboratories Allergenic Extracts is by diagnostic skin testing (See DOSAGE AND ADMINISTRATION — DIAGNOSIS). Physicians who administer allergenic extract should have emergency medication and equipment available to treat anaphylaxis (14). See Precautions, Adverse Reactions and Overdosage below.

To reduce the risk of anaphylaxis, the following measures must be observed: Concentrated extract must be diluted before use for intradermal skin testing and for beginning immunotherapy. It should never be injected intravenously during testing or treatment procedures. Patients who are highly sensitive, determined from clinical findings and test results, may require that treatment start with a very weak concentration of extract, such as 1:10,000,000 v/v.

The dosage of fresh (new) extract given to a patient receiving maintenance injections must be reduced to one-fourth the amount given from the previous (old) lot (See Immunotherapy, last paragraph). Patients who are transferred to standardized extract after previous treatment with unstandardized extract must be skin tested with serial dilutions, starting with a 1:100,000 v/v dilution of the standardized extract, to determine a safe, non-reacting starting dose. Patients who are transferred to this extract after treatment with alum precipitated or other modified extract must re-start injections with the beginning recommended dose of this extract.

🤒 Adverse Reactions ~2 min read ▾

ADVERSE REACTIONS Local Reactions: The occurrence of a hive 5 to 15 minutes after the subcutaneous injection of extract does not require a reduction in dosage. However, a local reaction with edema larger than 2 cm in diameter or swelling and redness that persist for several hours or longer indicates that too much extract has been given. Treatment should be altered as follows: Additional injections should not be given until all evidence of the reaction has disappeared.

The next injection administered should be 50% of the last non-reacting dose or less, depending upon the size and severity of the local reaction. Subsequent injections should be continued at the reduced dosage unless the physician responsible for treatment believes that it is safe to increase the dose, and that possible clinical improvement would result from the administration of a larger dose of extract. Systemic Reactions: Systemic (generalized) reactions may range from a mild exacerbation of the patient's allergic symptoms to hives, anaphylactic shock, or even death from anaphylaxis.

The reaction usually occurs 5 to 20 minutes after injection. As a rule, the more quickly a reaction develops, the more serious it is likely to become. Symptoms may include sneezing, coughing, itching, shortness of breath, abdominal cramps, vomiting, diarrhea, tachycardia, hypotension and respiratory failure in severe cases.

The reaction is usually stopped by the subcutaneous injection of Epinephrine HCl 1:1,000 (See Overdosage below). The oral administration of antihistamines and the placement of a tourniquet proximal to the injection site are helpful adjuncts. In the event that additional measures are required, it may be necessary to treat the patient for BRONCHOSPASM with intravenous aminophylline, intravenous fluids and corticosteroids; for HYPOTENSION with vasopressors, volume repletion, isoproterenol and corticosteroids; for LARYNGEAL OBSTRUCTION with oxygen and tracheostomy; and for CARDIAC ARREST with cardiopulmonary resuscitation and other appropriate measures.

Immunotherapy after anaphylaxis should only be continued if the cause of the reaction can be identified and appropriate precautions taken to insure that a subsequent reaction does not occur.

🆘 Overdosage 161 words ▾

OVERDOSAGE A strong local reaction to the injection of extract may be treated with oral antihistamines and the local application of a cold compress. The dosage must be reduced and additional extract must not be given until all evidence of the reaction has disappeared. A systemic reaction following the injection of extract must be treated immediately as follows (Ref. #4, vol.

2, p. 888): 0.01 mL/kg up to 0.2 mL of aqueous epinephrine HCl 1:1000 subcutaneously at the injection site of antigen. 0.01 mL/kg up to 0.3 mL of aqueous epinephrine HCl 1:1000 subcutaneously at another site.

Diphenhydramine intravenously or intramuscularly, 1.25 mg/kg up to 50 mg. Tourniquet above the injection site of antigen. Specific reactions: a.

Brochospasm: intravenous aminophylline 4 mg/kg up to 500 mg given over 10 to 15 minutes, aqueous hydrocortisone 5 mg/kg up to 200 mg, oxygen. b. Laryngeal edema: oxygen, intubation, tracheostomy. c. Hypotension: vasopressors, fluids, corticosteroids. d.

Cardiac arrest: resuscitation, sodium bicarbonate, defibrillation, antiarrhythmia medications.

🧬 Clinical Pharmacology 63 words ▾

CLINICAL PHARMACOLOGY Positive skin tests with allergenic extract are the result of histamine release from mast cells sensitized with allergen specific IgE. The exact mechanisms by which immunotherapy relieves symptoms of allergy are still under investigation. Elevations in allergen-specific IgG antibodies and an increase in the activity of T suppressor lymphocytes appear to be some of the immunologic changes that occur from hyposensitization.(1,2,3)

📦 How Supplied / Storage and Handling 46 words ▾

HOW SUPPLIED Allergenic extract is supplied in 5 mL dropper vials for scratch or prick testing and in 10, 30, and 50 mL vials for bulk use. Storage and Handling Extract should be stored at 2-8°C since higher temperatures may adversely affect stability. Do not freeze.

📋 Description 50 words ▾

DESCRIPTION Allergenic extract contains the aqueous extractables from allergenic source material in extracting solution containing 0.25% sodium chloride, 0.125% sodium bicarbonate, and 50% glycerol. 0.4% phenol is added as a preservative. The weight by volume value shown on the label is a measurement of extract concentration, rather than extract potency.

⚠️ Precautions ~1 min read ▾

PRECAUTIONS Extract should be stored at 2°C to 8°C since higher temperatures may adversely affect the stability of the product. Do not freeze. After the needle is inserted subcutaneously, the plunger should be withdrawn slightly to check for the presence of blood in the syringe.

If blood is observed, a new injection should be prepared and given at another site, observing the same precautions. Treatment with beta-blocking drugs may make patients refractory to the usual dose of epinephrine, in the event epinephrine is required to control an adverse allergic reaction. PREGNANCY CATEGORY C.

Allergenic extract. Animal reproduction studies have not been conducted with allergenic extract. It is also not known whether allergenic extract can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Allergenic extract should be given to a pregnant woman only if clearly needed. PATIENT INSTRUCTIONS: Patients should be instructed to remain in the physician's office for at least 20 minutes after skin testing and after each treatment injection, and immediately notify the physician if symptoms of a generalized reaction or shock occur. CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Long term studies have not been conducted with allergenic extracts to determine their potential for carcinogenesis, mutagenesis, and impairment of fertility.

NURSING MOTHERS: Data are not available on the secretion of allergenic extract in human milk and it is not known what affect this might have on the nursing infant. PEDIATRIC USE: The dose of allergenic extract recommended for children is the same as that used for adults, except in the injection of large doses of extract for treatment. In this case, the amount of extract given to a child may be modified so that the discomfort of the injection is minimized.

📚 References ~1 min read ▾

REFERENCES Levy, D.A., Lichtenstein, L.M., Goldstein, E.O. and Ishizaka, K. Immunologic and cellular changes accompanying the therapy of pollen allergy. J.

Clinical Investigations. 50:360, 1971. Evans, R., Pence, H., Kaplan, H., and Rocklin, R.

The effect of immunotherapy on humoral and cellular response in ragweed hayfever. J. Clinical Investigations.

57:1378, 1976. Ishizaka, K. Cellular events in the IgE antibody response.

Adv. In Immunology. 23:50, 1976.

Middleton, Elliott Jr., Reed, C.E. and Ellis, E.F. (Eds.) Allergy, Principles and Practice Vols. 1 & 2, C.V.

Mosby 1978. Sheldon, J.M., Lovell, R.G. and Matthews, K.P. A Manual of Clinical Allergy.

W.B. Saunders, 1967. Nelson, H.S.

Diagnostic procedures in allergy. I. Allergy skin testing.

Ann. Allergy. 51:411, 1983.

Norma, P.S., Winkenwerder, W.L., and Lichtenstein, L.M. Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos. J.

Allergy. 42:93, 1968. Milner, F.H. and Tees, E.C.

Specific sensitivity to individual grass pollens in some hay fever patients. Clinical Allergy. 2:83, 1972.

Frankland, A.W. and Augustine, R. Grass pollen antigens effective in treatment. Clinical Science.

23:95, 1962. Pence, H.L., Mitchell, D.Q., Greely, R.L., Updegraff, B.R. and Selfridge, H.A. Immunotherapy for mountain cedar pollinosis: a double-blind controlled study.

J. Allergy ad Clinical Immunology. 58:39, 1976.

Taylor, W.W., Ohman, J.L. Jr. and Lowell, F.C. Immunotherapy in cat-induced asthma.

Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J. Allergy and Clinical Immunology.

61:283. 1978. Lichtenstein, L.M., Valentine, M.D. and Sobotka, A.K.

Insect allergies. The state of the art. J.

Allergy and Clinical Immunology. 61:268, 1978. Metzger, W.J., Turner, E., and Patterson, R.

The safety of immunotherapy during pregnancy. J. Allergy and Clinical Immunology.

61:268. 1978. Ouellette, J.J.

Emergency management of allergic reactions. Modern Medicine 99, 1975.

📄 Package Label / Principal Display Panel 8 words ▾

PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - VIAL

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Mucor plumbeus — the ingredient across all brands.

Top reported reactions

Diarrhoea7
Decreased Appetite6
Pain5
Abdominal Pain4
Headache4
Malaise4
Vomiting4

Age at onset

Adult2

Reporter sex

45 reports
Male · 23%
Female · 77%

Serious outcomes

Hospitalization10
Disabling7
Life-threatening3
Death1
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 5 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Allermed Laboratories, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 5 ml (49643-0166-05), 10 ml (49643-0166-10), 50 ml (49643-0166-50). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Allermed Laboratories, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.